In a Healio video interview, Nancy M. Holekamp, MD, director of retina services at Pepose Vision Institute in St. Louis, discussed her ASRS presentation on ANX007, a novel C1q inhibitor for advanced dry age-related macular degeneration.
“With selective inhibition of C1q, you also shut down C3 and C5 as well as other classical pathway components C4 and C9, so there is a rationale to target the classical pathway, and this is the first molecule that hopes to do so,” Holekamp said.
Holekamp discussed an ongoing phase 2 clinical trial evaluating (Read more...)